David Roulois

David Roulois

Auto-generated profile, based on publicly available information

David Roulois

UMR 1236, Univ Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Cell
Verified
Journal Article
Closed access
DRDavid Roulois
David Roulois
HYHelen Loo Yau
Helen Loo Yau
RSRajat Singhania
Rajat Singhania
YWYadong Wang
Yadong Wang
ADArnavaz Danesh
Arnavaz Danesh
DCDaniel D. De Carvalho
Daniel D. De Carvalho

14 November 2018 in Nature
Verified
Journal Article
Closed access
PDF file
SSShu Yi Shen
Shu Yi Shen
RSRajat Singhania
Rajat Singhania
GFGordon Fehringer
Gordon Fehringer
ACAnkur Chakravarthy
Ankur Chakravarthy
MRMichael H. A. Roehrl
Michael H. A. Roehrl
DCDaniel D. De Carvalho
Daniel D. De Carvalho

18 June 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SNSaba Nayar
Saba Nayar
JCJoana Campos
Joana Campos
CSCharlotte G. Smith
Charlotte G. Smith
VIValentina Iannizzotto
Valentina Iannizzotto
DGDavid H. Gardner
David H. Gardner
FBFrancesca Barone
Francesca Barone
Significance: TLS, which are clusters of lymphocytes and stromal cells observed at sites of chronic inflammation, play a key role in sustaining disease progression in autoimmune conditions. While the role of lymphocytes in these structures has been studied extensively, the role of fibroblasts, nonhematopoietic stromal cells, in the formation and maintenance of TLS has not been demonstrated. Here, we establish that, at sites of TLS establishment, resident fibroblasts expand and acquire immunological features in a process that is dependent on IL13 and IL22. Interference with this process or depletion of immunofibroblasts leads to involution of TLS, resulting in decreased immune-cell activation and resolution of tissue pathology, thus supporting the use of fibroblast-targeting strategies to treat TLS-associated autoimmune diseases.

1 March 2013 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JGJean-Baptiste Guillerme
Jean-Baptiste Guillerme
NBNicolas Boisgerault
Nicolas Boisgerault
DRDavid Roulois
David Roulois
JMJérémie Ménager
Jérémie Ménager
CCChantal Combredet
Chantal Combredet
MGMarc Gregoire
Marc Gregoire
Purpose: Plasmacytoid dendritic cells (pDC) are antigen-presenting cells specialized in antiviral response. The measles virus vaccine is proposed as an antitumor agent to target and specifically kill tumor cells without infecting healthy cells. Experimental Design: Here, we investigated, in vitro, the effects of measles virus vaccine–infected tumor cells on the phenotype and functions of human pDC. We studied maturation and tumor antigen cross-presentation by pDC, exposed either to the virus alone, or to measles virus vaccine–infected or UV-irradiated tumor cells. Results: We found that only measles virus vaccine–infected cells induced pDC maturation with a strong production of IFN-α, whereas UV-irradiated tumor cells were unable to activate pDC. This IFN-α production was triggered by the interaction of measles virus vaccine single-stranded RNA (ssRNA) with TLR7. We observed that measles virus vaccine–infected tumor cells were phagocytosed by pDC. Interestingly, we showed cross-presentation of the tumor antigen NYESO-1 to a specific CD8+ T-cell clone when pDC were cocultured with measles virus vaccine–infected tumor cells, whereas pDC were unable to cross-present NYESO-1 after coculture with UV-irradiated tumor cells. Conclusions: Altogether, our results suggest that the use of measles virus vaccine in antitumor virotherapy induces immunogenic tumor cell death, allowing pDC to mature, produce high amounts of IFN-α, and cross-present tumor antigen, thus representing a mode of recruiting these antigen-presenting cells in the immune response. Clin Cancer Res; 19(5); 1147–58. ©2012 AACR.

10 September 2019 in Stem Cells
Verified
Journal Article
Open access
PDF file
CMCédric Ménard
Cédric Ménard
JDJoëlle Dulong
Joëlle Dulong
DRDavid Roulois
David Roulois
BHBenjamin Hébraud
Benjamin Hébraud
LVLéa Verdière
Léa Verdière
KTKarin TARTE
Karin TARTE
Clinical-grade mesenchymal stromal cells (MSCs) can be expanded from bone marrow and adipose tissue to treat inflammatory diseases and degenerative disorders. However, the influence of their tissue of origin on their functional properties, including their immunosuppressive activity, remains unsolved. In this study, we produced paired bone marrow-derived mesenchymal stromal cell (BM-MSC) and adipose-derived stromal cell (ASC) batches from 14 healthy donors. We then compared them using transcriptomic, phenotypic, and functional analyses and validated our results on purified native MSCs to infer which differences were really endowed by tissue of origin. Cultured MSCs segregated together owing to their tissue of origin based on their gene expression profile analyzed using differential expression and weighted gene coexpression network analysis. This translated into distinct immune-related gene signatures, phenotypes, and functional cell interactions. Importantly, sorted native BM-MSCs and ASCs essentially displayed the same distinctive patterns than their in vitro-expanded counterparts. As a whole, ASCs exhibited an immune profile consistent with a stronger inhibition of immune response and a lower immunogenicity, supporting the use of adipose tissue as a valuable source for clinical applications.

1 April 2021 in Molecular Cell
Verified
Journal Article
Closed access
HYHelen Loo Yau
Helen Loo Yau
EBEmma Bell
Emma Bell
IEIlias Ettayebi
Ilias Ettayebi
FAFelipe Campos de Almeida
Felipe Campos de Almeida
GBGiselle M. Boukhaled
Giselle M. Boukhaled
DCDaniel D. De Carvalho
Daniel D. De Carvalho